NICE Single Technology Appraisal Guidance No
230– Bivalirudin for the treatment
of ST-segment-elevation myocardial infarction
This NICE guidance was published
on27th July 2011. The web reference for the
appraisal and other related documents is: www.nice.org.uk/TA230
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (638/10) on
this medication for this indication in September 2010. This stated
that:
Bivalirudin (Angiox)is accepted for use within
NHS Scotland as an anticoagulant in adult patients undergoing
percutaneous coronary intervention (PCI), including patients with
ST-segment elevation myocardial infarction (STEMI) undergoing
primary PCI. Bivalirudin should be administered with aspirin and
clopidogrel. Its use is restricted topatients who would have been
considered for treatment with heparin in combination with a
glycoprotein IIb/IIIa inhibitor. It should not be used as an
alternative to heparin alone.
Access the advice of SMC:
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 27 July 2011
